doxofylline doxofylline doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma and copd. like theophylline, it is a xanthine derivative. doxofyllineclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationby mouthatc coder03da11 (who) legal statuslegal status in general: ℞ (prescription only) identifiers iupac name 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione cas number69975-86-6 ypubchem cid50942drugbankdb09273chemspider46175uniimpm23gmo7zkeggd03898 ycomptox dashboard (epa)dtxsid7022968 echa infocard100.067.468 chemical and physical dataformulac11h14n4o4molar mass266.257 g·mol−13d model (jsmol)interactive image smiles cn1c2=c(c(=o)n(c1=o)c)n(c=n2)cc3occo3 inchi inchi=1s/c11h14n4o4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7h,3-5h2,1-2h3key:hwxigfivgwuzao-uhfffaoysa-n (verify) medical uses doxophylline is used to treat chronic respiratory diseases such as asthma and copd. in animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects. in february 2014, the us fda granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by alitair pharmaceuticals, in may 2013. pharmacology unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. this suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase. from a pharmacokinetic point of view, doxofylline importantly differs from theophylline also because it lacks the ability to interfere with the cytochrome enzymes cyp1a2, cyp2e1 and cyp3a4, thus preventing significant interaction with other drugs metabolized via these pathways in the liver. concomitant treatment with certain other medications (including allopurinol, h2 receptor antagonists, lincosamide antibiotics, macrolide antibiotics, and propranolol) can decrease the hepatic clearance of doxofylline, which can result in increased serum levels of doxofylline. names it is marketed under many brand names worldwide, including: xiva, an li nuo er, an sai ma, ansimar, asima, bestofyline, chuan ning, d-fyal, dilatair, doxiba, doxiva, doxobid, doxobron, doxofilina, doxofillina, doxofyllin, doxoll, doxophylline, doxovent, doxyjohn, fei te ai si, jian fang neng, lang ming, lv meng, mai ping xi, maxivent, mucosma, na de lai, phylex, phyllin, puroxan, rexipin, shu zhi, shuai an, shuweixin, suo di, suo ji, suo li an, xi si nuo, xin qian ping, xin xi ping, yi suo, and yili. it is also marketed as a combination drug with terbutaline as doxoll-tl, mucosma-t and phylex-tr. it is also marketed as a combination drug with montelukast as doxoll-ml, doxomont, doxoril-m, doxovent-m, lunair-m, and venidox-m.